A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 674-678

  Barlaam, Bernard ^a   Ballard, Peter ^a   Bradbury, Robert H ^a   Ducray, Richard ^a   Germain, Hervé ^a   Hickinson, D Mark ^a   Hudson, Kevin ^a   Kettle, Jason G ^a   Klinowska, Teresa ^a   Magnien, Françoise ^a   Ogilvie, Donald J ^a   Olivier, Annie ^a   Pearson, Stuart E ^a   Scott, James S ^a   Suleman, Abid ^a   Trigwell, Cath B ^a   Vautier, Michel ^a   Whittaker, Robin D ^a   Wood, Robin ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anilinoquinazoline; C 5 substitution; erbB2 kinase inhibitor

Indexed keywords

4 ANILINOQUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUCOSE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; RAT; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38349057943     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.052     Document Type: Article

References (23)

1. Rowinski E.K. Horizons Cancer Ther. 2 (2001) 3 and references herein
2. Wallace E.M., Yeh T.C., Laird E.R., Blake J.F., and Lyssikatos J. In: Bradbury R.H. (Ed). Topics in Medicinal Chemistry (Cancer) (2007), Springer, Heidelberg 83
3. Gross M.E., Shazer R.L., and Agus D.B. Semin. Oncol. 31 (2004) 9 1 Suppl 3
4. Citri A., and Yarden Y. Nat. Rev. Mol. Cell Biol. 7 (2006) 505
5. Emens L.A., and Davidson N.E. Oncology 18 (2004) 1117
6. Lackey K. Curr. Top. Med. Chem. 6 (2006) 435
7. Script, 15 March 2006.
8. Hennequin L.F., Allen J., Breed J., Curwen J., Fennell M., Green T.P., Lambert van der Brempt C., Morgentin R., Norman R.A., Olivier A., Otterbein L., Ple P.A., Warin N., and Costello G. J. Med. Chem. 49 (2006) 6465-6488
9. Barlaam B., Fennell M., Germain H., Green T., Hennequin L., Morgentin R., Olivier A., Plé P., Vautier M., and Costello G. Bioorg. Med. Chem. Lett. 15 (2005) 5446
10. Ballard P., Bradbury R.H., Harris C.S., Hennequin L.F.A., Hickinson M., Johnson P.D., Kettle J.G., Klinowska T., Leach A.G., Morgentin R., Pass M., Ogilvie D.J., Olivier A., Warin N., and Williams E.J. Bioorg. Med. Chem. Lett. 16 (2006) 1633
11. Ballard P., Bradbury R.H., Hennequin L.F.A., Hickinson D.M., Johnson P.D., Kettle J.G., Klinowska T., Morgentin R., Ogilvie D.J., and Olivier A. Bioorg. Med. Chem. Lett. 15 (2005) 4226
12. Ballard P., Barlaam B.C., Bradbury R.H., Dishington A., Hennequin L.F.A., Hickinson D.M., Hollinsworth I.M., Kettle J.G., Klinowska T., Ogilvie D.J., Pearson S.E., Scott J.S., Suleman A., Whittaker R., Williams E.J., Wood R., and Wright L. Bioorg. Med. Chem. Lett. 17 (2007) 6326
13. For experimental procedures and hERG assay protocol, see: Bradbury, R. H.; Kettle, J. G.; Scott, J. S.; Barlaam, B. C. PCT Int. Appl. WO 2005118572. In particular, the synthesis of the aniline precursor of compounds 15-16 is described herein.
14. The phenol 24a resulted from the intramolecular nucleophilic attack of the anion of the acetamide (formed in the reaction conditions because of excess of sodium hydride) onto the ether adduct. This intermediate is formed by displacement of the fluoro group of 23a with sodium 2-acetamidoethoxide.
15. In the absence of amine, activation of the carboxylic acid with EDCI or HATU gave the activated anilide resulting from the intramolecular attack of the NH of the aniline onto the activated carboxylic acid; this activated anilide can be isolated and reacted with an amine to form the expected amide. Alternatively in the presence of the amine, activation of the carboxylic acid gave the expected amides with minor amounts of the activated anilide.
16. Good enantiomeric purity was observed with these methods: 19 and 21 made as described in Scheme 1 gave, respectively, 99.6% ee and >99.6% ee measured by chiral HPLC; 21 made in a similar manner as compounds in Scheme 2 gave 98.6% ee; however attempts to displace 23b with the (R)-N,N dimethyl lactamide in the presence of sodium hydride in THF at reflux gave partial racemisation.
17. Tasaka A., Tamura N., Matsushita Y., Teranishi K., Hayashi R., Okonogi K., and Itoh K. Chem. Pharm. Bull. 41 (1993) 1035
18. m ATP concentration for each enzyme: 14 kinases for 9 and >40 for 19 and 21.
19. Jamieson C., Moir E.M., Rankovic Z., and Wishart G. J. Med. Chem. 49 (2006) 5029
20. -1; about the MDCK-MDR permeability assay, see: Kerns, E. H.; Di, L.; Petusky, S.; Farris, M.; Ley, R.; Jupp, P. J. Pharm. Sci. 2004, 93, 1440.
21. Baselga J., Norton L., Albanell J., Kim Y.M., and Mendelsohn J. Cancer Res. 58 (1998) 2825
22. Balani S.K., Li P., Nguyen J., Cardoza K., Zeng H., Mu D.-X., Wu J.-T., Gan L.-S., and Lee F.W. Drug Metab. Disp. 32 (2004) 1092
23. Increased blood levels of 19 dosed at 100 mg/kg orally were seen after oral coadministration of 100 mg/kg of ABT (AUC 670 μM h vs 130 μM h without ABT and concentration at 8 h 23 μM vs 2 μM).